Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.38 |
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697886 | 0.84 | MAPK14 (0.41) | MAPK14MAPK13 | |
| SCHEMBL1343232 | 0.83 | CNR1 (0.42) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1342393 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1342802 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1343494 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1343502 | 0.81 | MAPK14 (0.40) | MAPK14MAPK13 | |
| SCHEMBL1340887 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1341986 | 0.81 | MAPK14 (0.38) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL1341694 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL4470766 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | SMN1; SMN2 3318/4885NPC1 2499/4885RAB9A 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.